Bluebird Is Sued Over Patents Related to BloodDisease Drug

Bluebird Is Sued Over Patents Related to Blood-Disease Drug

By Christopher Yasiejko 2021-10-21T17:56:54694-04:00

Bluebird Bio’s LentiGlobin and Zynteglo infringe two patents for recombinant vectors used in the treatment of rare blood disorders, closely held Errant Gene Therapeutics claims in a new lawsuit.

• Recombinant vectors deliver gene fragments used in vaccines to boost the immune system

• Bluebird in September submitted to FDA its application for beti-cel, made using BB305 lentiviral vector, and it’s marketing beti-cel as LentiGlobin for treating sickle cell disease and as Zynteglo for beta thalassemia, according to a complaint filed Thursday in federal court in Wilmington, Delaware

• Errant is seeking at least a reasonable royalty and either court order blocking commercialization activities related to BB305 vector until its patents have expired or ongoing royalties

• Errant says it “may seek a preliminary injunction”

• Errant on Oct. 5 filed suit in New York against Memorial Sloan-Kettering Cancer Center and Sloan Kettering Institute, asking court for declarations that two Errant vectors are covered by same patents, and that it has rights to make or sell them under “exclusive, royalty-free, commercial license” from Sloan Kettering

• NOTE: Ex-Trader Takes Sloan-Kettering to Court Over Gene Therapy

• CASE: Errant Gene Therapeutics LLC v. Bluebird Bio Inc., 21-cv-1478, U.S. District Court, District of Delaware (Wilmington)

View the rest of the article here

View the PDF